Results 1 to 10 of about 40,300 (234)

Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy [PDF]

Renal Failure, 2022
Background The value of anti-phospholipase A2 receptor antibody (anti-PLA2R ab) monitoring at 3 months after diagnosis in membranous nephropathy (MN) remains uncertain. Methods We retrospectively examined the outcome on 1 August 2020 of 59 adult patients
Gabriel Stefan, Simona Stancu, Adrian Zugravu, Otilia Popa, Dalia Zubidat, Nicoleta Petre, Gabriel Mircescu   +6 more
doaj   +5 more sources

Phospholipase A2 receptor-negative membranous nephropathy presenting as a rare renal manifestation of IgG4-related disease [PDF]

SAGE Open Medical Case Reports
IgG4-related disease is a fibroinflammatory condition characterized by dense lymphoplasmacytic infiltrates rich in IgG4-positive plasma cells affecting multiple organs.
Srikar Sama, Alexander Weickhardt, Preethi Subramanian, Pooja Reddy   +3 more
doaj   +4 more sources

Recurrence of Phospholipase A2 Receptor–Associated Membranous Nephropathy in the Absence of Serum Anti-Phospholipase A2 Receptor Antibodies Reappearance [PDF]

Kidney International Reports
Ilias Bensouna, Marion Delafosse, Claire Cartery, Thomas Stehlé, Clementine Rabate, Fanny Boullenger, David Buob, Jean-Jacques Boffa, Karine Dahan, Emmanuel Esteve   +9 more
doaj   +4 more sources

Neural epidermal growth factor-like 1 expression predicts end-stage renal disease in phospholipase A2 receptor–negative membranous nephropathy: A retrospective cohort stratified by systemic lupus erythematosus [PDF]

Journal of International Medical Research
Background Neural epidermal growth factor-like 1 protein has emerged as a significant antigen in membranous nephropathy, an important cause of nephrotic syndrome in adults.
Qingqing Rao, Yuan Cheng, Shuling Yue, Haiying Song, Wangyang Li, Dongli Qi, Qijun Wan   +6 more
doaj   +2 more sources

Hypercholesterolemia Correlates With Glomerular Phospholipase A2 Receptor Deposit and Serum Anti-Phospholipase A2 Receptor Antibody and Predicts Proteinuria Outcome in Idiopathic Membranous Nephropathy [PDF]

Frontiers in Immunology, 2022
BackgroundThe anti-phospholipase A2 receptor (PLA2R) antibody is a non-invasive diagnostic tool and prognosis predictor of idiopathic membranous nephropathy (IMN). Baseline hypercholesterolemia independently predicts proteinuria outcomes in IMN patients.
Lei Dong, Yue-qiang Li, Shui-ming Guo, Gang Xu, Wang Wei, Min Han   +5 more
doaj   +2 more sources

Anti-phospholipase A2 receptor antibodies directly induced podocyte damage in vitro [PDF]

Renal Failure, 2022
Background The pathogenesis of primary membranous nephropathy (MN) involves the antibodies against antigens on the cell surface of podocytes, with the majority of M-type phospholipase A2 receptor (PLA2R), and a profound podocyte dysfunction.
Yanfen Li, Juntao Yu, Miao Wang, Zhao Cui, Ming-hui Zhao   +4 more
doaj   +2 more sources

Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study

Renal Failure, 2020
Introduction Primary membranous nephropathy (PMN) is associated with the anti-phospholipase A2 receptor (anti-PLA2R) antibody in 70% of cases. Some anti-PLA2R-negative patients have the PLA2R antigen in renal tissue.
Peihong Yin, Junxian Wang, Wenyi Liang, Linda Zhan, Yuanhao Liu, Jian Lin, Xiaohong Chen, Yingqin He, Hongyun Jian, Zhibin Xie, Xiaofan Tan, Qing Ye, Fengxian Huang   +12 more
doaj   +2 more sources

Hypercoagulability and dyslipidemia in membranous nephropathy with anti-phospholipase A2 receptor antibodies [PDF]

Renal Failure
Michael Kitlinski, Zbigniew Heleniak, Alicja Dębska-Ślizień   +2 more
doaj   +2 more sources

Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion

Hepatology, EarlyView., 2022
The role of SMLR1 in lipid metabolism (high fat + cholesterol diet in mice) Abstract Background and Aims The assembly and secretion of VLDL from the liver, a pathway that affects hepatic and plasma lipids, remains incompletely understood. We set out to identify players in the VLDL biogenesis pathway by identifying genes that are co‐expressed with the ...
Willemien van Zwol, Antoine Rimbert, Justina C. Wolters, Marieke Smit, Vincent W. Bloks, Niels J. Kloosterhuis, Nicolette C. A. Huijkman, Mirjam H. Koster, Umesh Tharehalli, Simon M. de Neck, Colin Bournez, Marceline M. Fuh, Jeroen Kuipers, Sujith Rajan, Alain de Bruin, Henry N. Ginsberg, Gerard J. P. van Westen, M. Mahmood Hussain, Ludger Scheja, Joerg Heeren, Philip Zimmerman, Bart van de Sluis, Jan Albert Kuivenhoven   +22 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source